Reporters.io
Frank Vinluan
MedCity News
Profile
Contacts
Recent Articles on Subject
1
Frank Vinluan
MedCity News
Medical innovation tracker.
MedCity, USA
medical
innovation
Novo Nordisk Lands Lexicon Pharma Obesity Drug With Potential to Pair With GLP-1s
- 5 days ago
Rare Metabolic Disease That Leads to Childhood Obesity Gets Its First FDA-Approved Drug
- 6 days ago
FDA Approves First-in-Class GSK Antibiotic for Common Type of Urinary Tract Infection
- 7 days ago
Seeing a Better Way for Eye Drug R&D, Character Bio Lands $93M for Two Trials in Dry AMD
- 8 days ago
Anne Wojcicki Had a Fully Financed Plan to Take 23andMe Private. Then It Fell Apart.
- 9 days ago
Novo Nordisk Bets $200M on Triple-Targeting Drug for Obesity and Other Metabolic Diseases
- 9 days ago
Novo Nordisk Launches Lower-Cost Wegovy, Following Eli Lilly Into Direct-to-Patient Sales
- 28 days ago
VC Firm Sofinnova Partners Pulls In €1.2B to Deploy Across Life Sciences Investments
- 29 days ago
AbbVie Enters Obesity Field, Paying $350M for Amylin Receptor Agonist Already in the Clinic
- about 1 month ago
Praxis Presses Forward in Essential Tremor Despite Futility Finding From Trial Observers
- about 1 month ago
BridgeBio Oncology to Go Public in SPAC Deal Bringing $450M+ for Trio of Cancer Drugs
- about 1 month ago
Rare Disease Biotech Zevra Therapeutics to Sell FDA Drug Review Fast Pass for $150M
- about 1 month ago
Merck Is Embracing AI, But ‘We Always Have a Human in the Loop,’ Exec Says
- about 1 month ago
Bristol Myers Squibb Cancer Immunotherapy Flunks a Key Test in Melanoma
- about 2 months ago
Aardvark Therapeutics’ Pursuit of New Obesity Target Adds $94M in IPO Cash
- about 2 months ago
FDA Approval of Drug for Rare Tumors Enables SpringWorks to Challenge AstraZeneca
- about 2 months ago
Novartis’s $925M Anthos Acquisition Brings Back Cardio Drug That Stops Blood Clots
- about 2 months ago
Pliant Therapeutics Presses Pause on Clinical Trial for Lung Disorder Drug
- about 2 months ago
Vertex Pharma Challenger Sionna Secures $191M in IPO Cash for Cystic Fibrosis Pipeline
- about 2 months ago
Bain Capital Broadens Its Biotech Reach With $3.3B Deal for Mitsubishi Tanabe Pharma
- about 2 months ago
Denali’s Data in Rare Enzyme Deficiency Keep It on Pace to Seek Speedy FDA Approval
- about 2 months ago
Oral Metabolic Drug Acquired by Novo Nordisk Continues to Show Concerning Neuro Side Effects
- about 2 months ago
Supernus Wearable Device for Dosing Parkinson’s Drug Lands Long-Awaited FDA Approval
- about 2 months ago
Pfizer Drug Hits Goals of Colorectal Cancer Study, Clearing Way to Seek Full FDA Approval
- about 2 months ago
Metsera’s IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1s
- about 2 months ago
Vertex Pharma’s Opioid Alternative Wins FDA Approval, First in a New Class of Pain Meds
- 2 months ago
FDA Nod Paves Way for AstraZeneca Drug to Become New Standard of Care in Rare Blood Cancer
- 3 months ago
Galapagos CEO Tells JPM Audience the Rationale for Planned Business Separation
- 3 months ago
At JPM, Eli Lilly’s CEO Explains Why Mounjaro, Zepbound Sales Were Lower Than Expected
- 3 months ago
J&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies
- 3 months ago
Galapagos Keeps Focus on Cancer Cell Therapy, Spins Out Rest of Biz Into NewCo Backed by €2.4B
- 3 months ago
Biopharma in 2025: Outlook for Obesity Meds, Drug Prices, Regulation & More
- 3 months ago
Novo Nordisk Adds Obesity and Diabetes to AI Drug Research Pact With Flagship’s Valo Health
- 3 months ago
A Startup’s €90M Financing for Oral Peptide Drugs Includes Backing from Eli Lilly
- 3 months ago
FDA Wraps Up 2024 Handing Out Several Notable Regulatory Decisions
- 3 months ago
Pfizer Ends Sangamo Alliance With Gene Therapy for Hemophilia on Cusp of FDA Filing
- 3 months ago
Axsome Aims for FDA Filing in Alzheimer’s Agitation Despite Mixed Bag of Phase 3 Data
- 3 months ago
Bristol Myers Squibb Wins FDA Nod for Injectable Version of Blockbuster Cancer Drug
- 3 months ago
The Chase for Novel Oral GLP-1 Obesity Meds Adds a New Contender
- 3 months ago
Bristol Myers Squibb’s Sotyktu Meets Goals in Two Pivotal Psoriatic Arthritis Studies
- 3 months ago
Eli Lilly’s Zepbound Becomes First FDA-Approved Drug Therapy for Sleep Apnea
- 3 months ago
Startup SiteOne Secures $100M to Forge Ahead With Novel Non-Opioid Pain Meds
- 4 months ago
Teva and Sanofi Mid-Stage Data Reveal Shows Best-in-Class Potential for IBD Drug
- 4 months ago
Neurocrine Lands FDA Nod for First New Treatment in Decades for Rare Endocrine Disorder
- 4 months ago
Novo Nordisk Adds to Manufacturing Capacity, Pumping Billions Into New Rare Disease Site
- 4 months ago
ASH 2024 Recap: Movement in Multiple Myeloma, Cell Therapy, Sickle Cell Disease & More
- 4 months ago
AI Biotech BenevolentAI Restructures Again, This Time to Return to Its TechBio Roots
- 4 months ago
Safety Stands Out in Arcellx Cell Therapy’s ASH Data, But Don’t Overlook Manufacturing Advantages
- 4 months ago
GSK Multiple Myeloma Drug’s DREAMM Comeback Continues With Phase 3 Data at ASH
- 4 months ago
Safety Signal in Phase 2 Deals a Setback to BioAge Labs’ Muscle-Preserving Obesity Drug
- 4 months ago